Coronavirus Update: EU Regulator Skeptical On Vaccine This Year, Takeda Prepares Hyperimmune Alliance
Plus: Fujitsu Pledges Open IP, Zydus Cadila Secure Testing Kit Manufacturing
Executive Summary
EMA leader doesn't share Oxford's optimism, Takeda-led alliance forges ahead with plasma-derived therapy plans, Indian pharma firm Cadila gets into testing kits.
You may also be interested in...
EMA on COVID-19: 'Fast-Tracking Does Not Mean Cutting Corners'
EMA advises caution on COVID-19 vaccine timelines, but says the outlook is more promising for new treatments.
Coronavirus Update: AstraZeneca To Develop Oxford’s Vaccine, Adaptive Trial Delivers Remdesivir's Good News
AstraZeneca is to develop and distribute Oxford's COVID-19 vaccine candidate in collaboration with Vaccitech. Its developers believe it could be available as early as September.
With Interferon, Zydus Cadila Launches Third Salvo Against COVID-19
Cadila Healthcare is evaluating the use of pegylated interferon alpha-2b to treat COVID-19 and will explore the possibility of approval in the US under the compassionate use program. This marks the company’s third front to fight the disease after hydroxychloroquine and a vaccine.